Lawless MW - Search Results

1

Characterization of tumour necrosis factor-alpha genetic variants and mRNA expression in patients with severe sepsis.

O'Dwyer MJ, Mankan AK, Ryan AW, Lawless MW, Stordeur P, Kelleher D, McManus R, Ryan T. O'Dwyer MJ, et al. Among authors: lawless mw. Int J Immunogenet. 2008 Aug;35(4-5):279-85. doi: 10.1111/j.1744-313X.2008.00773.x. Epub 2008 Jul 17. Int J Immunogenet. 2008. PMID: 18643840

2

The human response to infection is associated with distinct patterns of interleukin 23 and interleukin 27 expression.

O'Dwyer MJ, Mankan AK, White M, Lawless MW, Stordeur P, O'Connell B, Kelleher DP, McManus R, Ryan T. O'Dwyer MJ, et al. Among authors: lawless mw. Intensive Care Med. 2008 Apr;34(4):683-91. doi: 10.1007/s00134-007-0968-5. Epub 2008 Jan 29. Intensive Care Med. 2008. PMID: 18227999

3

Highly sensitivity adhesion molecules detection in hereditary haemochromatosis patients reveals altered expression.

Norris S, White M, Mankan AK, Lawless MW. Norris S, et al. Among authors: lawless mw. Int J Immunogenet. 2010 Apr;37(2):125-33. doi: 10.1111/j.1744-313X.2010.00904.x. Epub 2010 Feb 19. Int J Immunogenet. 2010. PMID: 20193033

4

Elevated MCP-1 serum levels are associated with the H63D mutation and not the C282Y mutation in hereditary hemochromatosis.

Lawless MW, White M, Mankan AK, O'Dwyer MJ, Norris S. Lawless MW, et al. Tissue Antigens. 2007 Oct;70(4):294-300. doi: 10.1111/j.1399-0039.2007.00895.x. Tissue Antigens. 2007. PMID: 17767550

5

Targeting histone deacetylases for the treatment of immune, endocrine & metabolic disorders.

Lawless MW, Norris S, O'Byrne KJ, Gray SG. Lawless MW, et al. Endocr Metab Immune Disord Drug Targets. 2009 Mar;9(1):84-107. doi: 10.2174/187153009787582441. Endocr Metab Immune Disord Drug Targets. 2009. PMID: 19275684 Review.

6

Targeting histone deacetylases for the treatment of disease.

Lawless MW, Norris S, O'Byrne KJ, Gray SG. Lawless MW, et al. J Cell Mol Med. 2009 May;13(5):826-52. doi: 10.1111/j.1582-4934.2008.00571.x. Epub 2008 Nov 3. J Cell Mol Med. 2009. PMID: 19175682 Free PMC article. Review.

7

Histone deacetylase inhibitors target diabetes via chromatin remodeling or as chemical chaperones?

Lawless MW, O'Byrne KJ, Gray SG. Lawless MW, et al. Curr Diabetes Rev. 2009 Aug;5(3):201-9. doi: 10.2174/157339909788920956. Curr Diabetes Rev. 2009. PMID: 19689255 Review.

8

Unmasking the pathological and therapeutic potential of histone deacetylases for liver cancer.

Zhao J, Gray SG, Greene CM, Lawless MW. Zhao J, et al. Among authors: lawless mw. Expert Rev Gastroenterol Hepatol. 2019 Mar;13(3):247-256. doi: 10.1080/17474124.2019.1568870. Epub 2019 Jan 29. Expert Rev Gastroenterol Hepatol. 2019. PMID: 30791763 Review.

9

Antiviral activity of bone morphogenetic proteins and activins.

Eddowes LA, Al-Hourani K, Ramamurthy N, Frankish J, Baddock HT, Sandor C, Ryan JD, Fusco DN, Arezes J, Giannoulatou E, Boninsegna S, Chevaliez S, Owens BMJ, Sun CC, Fabris P, Giordani MT, Martines D, Vukicevic S, Crowe J, Lin HY, Rehwinkel J, McHugh PJ, Binder M, Babitt JL, Chung RT, Lawless MW, Armitage AE, Webber C, Klenerman P, Drakesmith H. Eddowes LA, et al. Among authors: lawless mw. Nat Microbiol. 2019 Feb;4(2):339-351. doi: 10.1038/s41564-018-0301-9. Epub 2018 Dec 3. Nat Microbiol. 2019. PMID: 30510168 Free PMC article.

10

The therapeutic properties of resminostat for hepatocellular carcinoma.

Zhao J, Gray SG, Wabitsch M, Greene CM, Lawless MW. Zhao J, et al. Among authors: lawless mw. Oncoscience. 2018 Jun 23;5(5-6):196-208. doi: 10.18632/oncoscience.420. eCollection 2018 May. Oncoscience. 2018. PMID: 30035186 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

44 results

Search Page

Filters